Skip to main content

Partners

Melissa Weiss, Associate Editor
While anyone can present with rosacea, this condition is often underdiagnosed among patients with darker phototypes. Dr Susan Taylor shares her clinical pearls for identifying rosacea in patients with skin of color.
Lauren Mateja, Managing Editor
As research continues to better differentiate between eczema and other diagnoses, the National Eczema Association continues to push awareness among patients and physicians with Eczema Awareness Month.
Lauren Mateja, Managing Editor
Lynn McKinley-Grant, MD, FAAD details what you need to remember when diagnosing and treating psoriasis in patients of color.
Peter Sonnenreich, Contributing Writer
New biologic therapy tralokinumab, a human monoclonal antibody targeting IL-13, is under FDA review for the treatment of atopic dermatitis.
Jonmichael W. Samsel, BS, Courtney E. Heron, BS, Steven R. Feldman, MD, PhD, Sarah L. Taylor, MD, MPH
Patients often describe seeking alternatives and adjuncts to care for the treatment of their atopic dermatitis. The literature has explored some of the potential in these options.
Joel M. Gelfand, MD, MSCE
Phototherapy continues to be a mainstay of psoriasis treatment. Dr Gelfand highlights recommendations for phototherapy administration and patient discussions during the COVID-19 pandemic.
Sarah Patton, MSHS, PA-C
The time away from clinic due to the pandemic has left many with time to contemplate current affairs and their dermatology practice. Sarah Patton, MSHS, PA-C, reflects on how her life and career has changed over the course of 4 months.
Lauren Mateja, Managing Editor
In an interview with The Dermatologist, Julie Harper, MD, discussed ways dermatologists can be more proactive in their treatment of rosacea.
While much of research is to test the clinical efficacy and safety of drugs, these posters from the American Academy of Dermatology Virtual Meeting Experience 2020 focused on physician decision-making and evaluation, patient characteristics, and disease severity of eczema.
Lauren Mateja, Managing Editor
Kristian Reich, MD, PhD, discussed a therapeutic breakthrough with bimekizumab, a novel biologic in development that inhibits IL-17F in addition to IL-17A.
Back to Top